HPM Partners LLC Has $1.67 Million Position in Stryker Co. (NYSE:SYK)

HPM Partners LLC grew its stake in Stryker Co. (NYSE:SYK) by 4.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,904 shares of the medical technology company’s stock after purchasing an additional 467 shares during the quarter. HPM Partners LLC’s holdings in Stryker were worth $1,672,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of SYK. Cozad Asset Management Inc. bought a new position in Stryker during the 2nd quarter worth about $298,000. Salem Investment Counselors Inc. increased its holdings in Stryker by 25.2% during the 2nd quarter. Salem Investment Counselors Inc. now owns 1,987 shares of the medical technology company’s stock worth $336,000 after purchasing an additional 400 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in Stryker by 354,407.4% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 95,717 shares of the medical technology company’s stock worth $135,000 after purchasing an additional 95,690 shares in the last quarter. Centaurus Financial Inc. bought a new position in Stryker during the 2nd quarter worth about $110,000. Finally, Metropolitan Life Insurance Co. NY increased its holdings in Stryker by 0.9% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 66,006 shares of the medical technology company’s stock worth $11,146,000 after purchasing an additional 592 shares in the last quarter. 75.11% of the stock is currently owned by institutional investors.

In other news, CFO Glenn S. Boehnlein sold 750 shares of Stryker stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $178.17, for a total value of $133,627.50. Following the completion of the sale, the chief financial officer now directly owns 2,785 shares in the company, valued at $496,203.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the completion of the sale, the vice president now owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The disclosure for this sale can be found here. Company insiders own 7.30% of the company’s stock.

SYK has been the subject of a number of research reports. Zacks Investment Research cut Stryker from a “buy” rating to a “sell” rating in a report on Wednesday, July 18th. BTIG Research initiated coverage on Stryker in a report on Thursday, August 16th. They set a “buy” rating and a $187.00 target price for the company. Cantor Fitzgerald reiterated a “hold” rating and set a $170.00 target price on shares of Stryker in a report on Wednesday, June 13th. ValuEngine cut Stryker from a “buy” rating to a “hold” rating in a report on Tuesday, June 12th. Finally, Sanford C. Bernstein assumed coverage on Stryker in a report on Wednesday, June 27th. They issued a “market perform” rating and a $177.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $178.33.

Shares of SYK stock opened at $175.00 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.83 and a quick ratio of 1.15. The company has a market cap of $66.45 billion, a price-to-earnings ratio of 26.96, a P/E/G ratio of 2.49 and a beta of 0.59. Stryker Co. has a 12-month low of $143.55 and a 12-month high of $179.84.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.73 by $0.03. The firm had revenue of $3.32 billion during the quarter, compared to the consensus estimate of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $1.53 earnings per share. On average, sell-side analysts anticipate that Stryker Co. will post 7.25 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, September 27th. This represents a $1.88 annualized dividend and a yield of 1.07%. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: What Are Treasury Bonds?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply